來源:[1] 川普、禮來、諾和諾德公佈肥胖藥物降價協議 (https://www.cnbc.com/2025/11/06/trump-eli-lil ...)[2] 禮來公佈亮眼第三季度業績:長期上漲空間巨大 | Investing.com (https://www.investing.com/analysis/eli-lilly- ...)[3] 肥胖藥物市場競爭白熱化 - DCAT 價值鏈洞察 (https://www.dcatvci.com/14187-novo-nordisk-pf ...)